A phase II study to assess the safety, tolerability and efficacy of SPD503 [guanfacine] administered to children and adolescents aged 6-17 with attention-deficit/hyperactivity disorder (ADHD).
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Guanfacine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Shire
- 20 Nov 2005 New trial record.